When Bristol-Myers Squibb and Pfizer launched their new anticoagulant, Eliquis, early last year, Wall Street analysts predicted it would be a $3-billion-a-year blockbuster. After more than a year of struggling to reach that goal, the companies got some good news late Friday, when the FDA approved the drug to reduce the risk of blood clots in the legs and lungs following hip or knee replacement surgery.
Promising data could spell a new recommendation for Pfizer's Prevnar 13 pneumococcal vaccine in older adults, adding up to $1 billion in global sales. But some of Prevnar 13's sales will ride on Pfizer's marketing success with the 65-and-over crowd--which has proven a tough nut to crack for competitor Merck.
Pfizer's Prevnar 13 vaccine slashed the number of pneumonia cases in older adults, according to details from a new study that could add up to $1 billion to its global sales.
One of Pfizer's top-selling products is suddenly vulnerable to generic competition 18 months earlier than expected. A U.S. court nixed a key Celebrex patent, putting the pain drug up for a sales fight in May. And generics makers Mylan and Actavis are promising to launch their versions as soon as Pfizer's monopoly expires.
Last month Pfizer presented positive headline results from its massive Prevnar 13 trial, but the release was light on the details that could shape whether the data leads to an expanded recommendation. Now Pfizer has published a closer look at the data, and not everyone likes what they see.
The FDA's new guidelines for pill design may be the stick driving drugmakers to consider medication errors when blueprinting their drugs. But there's a carrot, too. With new tablet technologies, companies have more freedom to build their brands by making their pills distinctive.
Pfizer, which boosted production at its plant in Indonesia in 2012, is expanding there again.
Pfizer, which had to recall an injectable drug last month, is now recalling three lots of an antidepressant after a pharmacist discovered a capsule of one of Pfizer's heart pills in an Effexor XR bottle, a potentially deadly combo.
India's Ranbaxy Laboratories has issued another recall for its generic Lipitor, but a series of product recalls in recent weeks have come from plants around the world and companies as varied as Pfizer, Mylan and Gilead Sciences.
Reaping the benefits of deep-seated R&D reorganization, GlaxoSmithKline had the industry's best 6-year run of FDA nods for new drugs, according to EvaluatePharma, leading its competitors by a wide margin and leaving approval-starved outfits like Eli Lilly and Merck in the dust.